{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:24:51Z","timestamp":1786987491683,"version":"build-2736575974"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.coviro.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T20:24:33Z","timestamp":1543263873000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Broadly protective influenza vaccines: design and production platforms"],"prefix":"10.1016","volume":"34","author":[{"given":"Husni","family":"Elbahesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulietta","family":"Saletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guus F","family":"Rimmelzwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2018.11.005_bib0005","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev.pathmechdis.3.121806.154316","article-title":"The pathology of influenza virus infections","volume":"3","author":"Taubenberger","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0010","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.1213362","article-title":"Airborne transmission of influenza A\/H5N1 virus between ferrets","volume":"336","author":"Herfst","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.coviro.2018.11.005_bib0015","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature10831","article-title":"Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA\/H1N1 virus in ferrets","volume":"486","author":"Imai","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2018.11.005_bib0020","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/507558","article-title":"Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease","volume":"194","author":"Thompson","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.11.005_bib0025","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature07231","article-title":"Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors","volume":"455","author":"Yu","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2018.11.005_bib0030","doi-asserted-by":"crossref","DOI":"10.2807\/ese.15.05.19478-en","article-title":"High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland","volume":"15","author":"Ikonen","year":"2010","journal-title":"Euro Surveill"},{"key":"10.1016\/j.coviro.2018.11.005_bib0035","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0140-6736(09)62194-2","article-title":"Serological surveys for 2009 pandemic influenza A H1N1","volume":"375","author":"Reed","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2018.11.005_bib0040","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa0906453","article-title":"Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus","volume":"361","author":"Hancock","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0045","article-title":"Harnessing the power of T cells: the promising hope for a universal influenza vaccine","volume":"6","author":"Clemens","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.coviro.2018.11.005_bib0050","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.vaccine.2014.11.054","article-title":"Virus-specific T cells as correlate of (cross-)protective immunity against influenza","volume":"33","author":"Altenburg","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_bib0055","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1099\/vir.0.033076-0","article-title":"Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells","volume":"92","author":"Hillaire","year":"2011","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0060","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.vaccine.2006.08.036","article-title":"Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice","volume":"25","author":"Kreijtz","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_bib0065","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1016\/j.vaccine.2009.05.079","article-title":"Infection of mice with a human influenza A\/H3N2 virus induces protective immunity against lethal infection with influenza A\/H5N1 virus","volume":"27","author":"Kreijtz","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002381","article-title":"Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates","volume":"7","author":"Weinfurter","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2018.11.005_bib0075","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0080","doi-asserted-by":"crossref","first-page":"6833","DOI":"10.1038\/ncomms7833","article-title":"Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells","volume":"6","author":"Wang","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2018.11.005_bib0085","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1164\/rccm.201411-1988OC","article-title":"Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the flu watch cohort study","volume":"191","author":"Hayward","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coviro.2018.11.005_bib0090","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1016\/j.vaccine.2017.07.053","article-title":"The 2003 world health assembly resolution on seasonal influenza vaccination coverage and the 2009 influenza pandemic have had very little impact on improving influenza control and pandemic preparedness","volume":"35","author":"Palache","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_bib0095","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/303706a0","article-title":"Evidence for host-cell selection of influenza virus antigenic variants","volume":"303","author":"Schild","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2018.11.005_bib0100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.virol.2006.02.020","article-title":"Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs","volume":"350","author":"Widjaja","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2018.11.005_bib0105","doi-asserted-by":"crossref","first-page":"8148","DOI":"10.1038\/ncomms9148","article-title":"Development of high-yield influenza A virus vaccine viruses","volume":"6","author":"Ping","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2018.11.005_bib0110","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/cid\/ciy350","article-title":"Role of egg-adaptation mutations in low influenza A(H3N2) vaccine effectiveness during the 2012-13 season","volume":"67","author":"Skowronski","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2018.11.005_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092153","article-title":"Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses","volume":"9","author":"Skowronski","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2018.11.005_bib0120","article-title":"Egg-independent influenza vaccines and vaccine candidates","volume":"5","author":"Manini","year":"2017","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.coviro.2018.11.005_bib0125","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1016\/S0264-410X(01)00053-6","article-title":"Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains","volume":"19","author":"Tree","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_bib0130","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1586\/erv.11.82","article-title":"The future of cell culture-based influenza vaccine production","volume":"10","author":"Perdue","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2018.11.005_bib0135","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.vaccine.2009.02.064","article-title":"Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK","volume":"27","author":"Minor","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_bib0140","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1126\/science.1192517","article-title":"Induction of broadly neutralizing H1N1 influenza antibodies by vaccination","volume":"329","author":"Wei","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.coviro.2018.11.005_bib0145","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1146\/annurev.iy.08.040190.003513","article-title":"Structural basis of immune recognition of influenza virus hemagglutinin","volume":"8","author":"Wilson","year":"1990","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0150","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0140-6736(99)03311-5","article-title":"Human infection with influenza H9N2","volume":"354","author":"Peiris","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2018.11.005_bib0155","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1073\/pnas.0308352100","article-title":"Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome","volume":"101","author":"Fouchier","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2018.11.005_bib0160","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1378\/chest.129.1.156","article-title":"Avian influenza virus infections in humans","volume":"129","author":"Wong","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.coviro.2018.11.005_bib0165","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1086\/504723","article-title":"Distribution of amantadine-resistant H5N1 avian influenza variants in Asia","volume":"193","author":"Cheung","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.11.005_bib0170","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/JVI.01783-09","article-title":"Molecular determinants of adaptation of highly pathogenic avian influenza H7N7 viruses to efficient replication in the human host","volume":"84","author":"de Wit","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0175","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1099\/vir.0.053959-0","article-title":"Co-incorporation of the PB2 and PA polymerase subunits from human H3N2 influenza virus is a critical determinant of the replication of reassortant ribonucleoprotein complexes","volume":"94","author":"Hara","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0180","article-title":"Molecular basis of efficient replication and pathogenicity of H9N2 avian influenza viruses in mice","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2018.11.005_bib0185","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1128\/JVI.00130-16","article-title":"Multiple natural substitutions in avian influenza A virus PB2 facilitate efficient replication in human cells","volume":"90","author":"Manz","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0190","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1126\/science.1244730","article-title":"Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution","volume":"342","author":"Koel","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0195","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1128\/JVI.02962-14","article-title":"Identification of amino acid substitutions supporting antigenic change of influenza A(H1N1)pdm09 viruses","volume":"89","author":"Koel","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0200","first-page":"e01070","article-title":"Antigenic variation of clade 2.1 H5N1 virus is determined by a few amino acid substitutions immediately adjacent to the receptor binding site","volume":"5","author":"Koel","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2018.11.005_bib0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001211","article-title":"Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain","volume":"6","author":"Das","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2018.11.005_bib0210","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005996","article-title":"Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses","volume":"5","author":"Medina","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0215","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.vaccine.2017.02.066","article-title":"Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: a phase 3, randomized noninferiority study","volume":"35","author":"Treanor","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_bib0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4161\/hv.8.1.17623","article-title":"The rationale for quadrivalent influenza vaccines","volume":"8","author":"Ambrose","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coviro.2018.11.005_bib0225","doi-asserted-by":"crossref","first-page":"643","DOI":"10.15585\/mmwr.mm6722a5","article-title":"Update: ACIP recommendations for the use of quadrivalent live attenuated influenza vaccine (LAIV4) - United States, 2018-19 influenza season","volume":"67","author":"Grohskopf","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.coviro.2018.11.005_bib0230","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.idc.2017.11.005","article-title":"Updates on influenza vaccination in children","volume":"32","author":"Campbell","year":"2018","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0235","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.vaccine.2016.08.018","article-title":"Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: process challenges and success stories","volume":"34","author":"Rudenko","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_bib0240","doi-asserted-by":"crossref","first-page":"A40","DOI":"10.1016\/j.vaccine.2011.04.122","article-title":"Live attenuated pandemic influenza vaccine: clinical studies on A\/17\/California\/2009\/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries","volume":"29","author":"Rudenko","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_bib0245","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(16)00129-8","article-title":"Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies","volume":"16","author":"Belongia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2018.11.005_bib0250","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.vaccine.2015.11.010","article-title":"Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States","volume":"34","author":"Caspard","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_bib0255","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/cid\/ciw635","article-title":"2014-2015 influenza vaccine effectiveness in the United States by vaccine type","volume":"63","author":"Zimmerman","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2018.11.005_bib0260","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.coi.2018.04.015","article-title":"Influenza vaccines:\u2019 tailor-made\u2019 or\u2019 one fits all\u2019","volume":"53","author":"Saletti","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0265","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/14760584.2017.1299576","article-title":"Strategies to induce broadly protective antibody responses to viral glycoproteins","volume":"16","author":"Krammer","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2018.11.005_bib0270","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0275","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-017-0026-4","article-title":"A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies","volume":"2","author":"Nachbagauer","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0280","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2018.11.005_bib0285","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1128\/jvi.67.5.2552-2558.1993","article-title":"A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains","volume":"67","author":"Okuno","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0290","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coviro.2018.11.005_bib0295","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1222908","article-title":"Highly conserved protective epitopes on influenza B viruses","volume":"337","author":"Dreyfus","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.coviro.2018.11.005_bib0300","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2018.11.005_bib0305","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028852","article-title":"Is it possible to develop a \"universal\" influenza virus vaccine? Outflanking antibody immunodominance on the road to universal influenza vaccination","volume":"10","author":"Angeletti","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0310","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028845","article-title":"Is it possible to develop a \"universal\" influenza virus vaccine? Potential target antigens and critical aspects for a universal influenza vaccine","volume":"10","author":"Krammer","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0315","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.coviro.2018.11.005_bib0320","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00018-10","article-title":"Influenza virus vaccine based on the conserved hemagglutinin stalk domain","volume":"1","author":"Steel","year":"2010","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2018.11.005_bib0325","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1128\/JVI.00641-13","article-title":"Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies","volume":"87","author":"Krammer","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0330","doi-asserted-by":"crossref","first-page":"22666","DOI":"10.1038\/srep22666","article-title":"Stalking influenza by vaccination with pre-fusion headless HA mini-stem","volume":"6","author":"Valkenburg","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2018.11.005_bib0335","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00286-17","article-title":"Chimeric hemagglutinin constructs induce broad protection against influenza B virus challenge in the mouse model","volume":"91","author":"Ermler","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0340","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/vaccines3020239","article-title":"Developing universal influenza vaccines: hitting the nail, not just on the head","volume":"3","author":"Wiersma","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.coviro.2018.11.005_bib0345","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbrc.2013.10.041","article-title":"A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains","volume":"441","author":"Doyle","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.coviro.2018.11.005_bib0350","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.antiviral.2013.09.018","article-title":"Universal anti-neuraminidase antibody inhibiting all influenza A subtypes","volume":"100","author":"Doyle","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.11.005_bib0355","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.3390\/v6062465","article-title":"In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen","volume":"6","author":"Wohlbold","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2018.11.005_bib0360","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1099\/0022-1317-22-1-35","article-title":"The significance of influenza virus neuraminidase in immunity","volume":"22","author":"Rott","year":"1974","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040059","article-title":"Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans","volume":"4","author":"Sandbulte","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0370","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02332-17","article-title":"NAction! how can neuraminidase-based immunity contribute to better influenza virus vaccines?","volume":"9","author":"Krammer","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2018.11.005_bib0375","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1084\/jem.165.2.408","article-title":"Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes","volume":"165","author":"Gotch","year":"1987","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2018.11.005_bib0380","first-page":"3478","article-title":"Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals","volume":"118","author":"Lee","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2018.11.005_bib0385","doi-asserted-by":"crossref","first-page":"12057","DOI":"10.1128\/JVI.05204-11","article-title":"Characterization of the human CD8(+) T cell response following infection with 2009 pandemic influenza H1N1 virus","volume":"85","author":"Hillaire","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0390","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1099\/vir.0.048652-0","article-title":"Human T-cells directed to seasonal influenza A virus cross-react with 2009 pandemic influenza A (H1N1) and swine-origin triple-reassortant H3N2 influenza viruses","volume":"94","author":"Hillaire","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0395","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/JVI.02843-13","article-title":"Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus","volume":"88","author":"van de Sandt","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0400","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/267354a0","article-title":"Cytotoxic T cells kill influenza virus infected cells but do not distinguish between serologically distinct type A viruses","volume":"267","author":"Zweerink","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2018.11.005_bib0405","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1128\/JVI.02694-07","article-title":"Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus","volume":"82","author":"Kreijtz","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0410","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00232-18","article-title":"Variation at extra-epitopic amino acid residues influences suppression of influenza virus replication by M158-66 epitope-specific CD8(+) T lymphocytes","volume":"92","author":"van de Sandt","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0415","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/infdis\/jiy218","article-title":"H1N1pdm09 influenza virus and its descendants lack extra-epitopic amino acid residues associated with reduced recognition by M158-66-specific CD8+ T cells","volume":"218","author":"van de Sandt","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.11.005_bib0420","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1073\/pnas.1603106113","article-title":"Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses","volume":"113","author":"Valkenburg","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2018.11.005_bib0425","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1073\/pnas.1302935110","article-title":"Preemptive priming readily overcomes structure-based mechanisms of virus escape","volume":"110","author":"Valkenburg","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2018.11.005_bib0430","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1038\/ncomms3663","article-title":"Acute emergence and reversion of influenza A virus quasispecies within CD8+ T cell antigenic peptides","volume":"4","author":"Valkenburg","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2018.11.005_bib0435","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1128\/JVI.78.10.5216-5222.2004","article-title":"A mutation in the HLA-B2705-restricted NP383-391 epitope affects the human influenza A virus-specific cytotoxic T-lymphocyte response in vitro","volume":"78","author":"Berkhoff","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0440","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1099\/vir.0.82120-0","article-title":"Assessment of the extent of variation in influenza A virus cytotoxic T-lymphocyte epitopes by using virus-specific CD8+ T-cell clones","volume":"88","author":"Berkhoff","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0445","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1084\/jem.191.11.1853","article-title":"Viral escape by selection of cytotoxic T cell-resistant variants in influenza A virus pneumonia","volume":"191","author":"Price","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2018.11.005_bib0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001039","article-title":"Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold","volume":"6","author":"Valkenburg","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2018.11.005_bib0455","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmicb.2018.00123","article-title":"Universal vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture","volume":"9","author":"Rajao","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0460","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3389\/fimmu.2018.00600","article-title":"Novel platforms for the development of a universal influenza vaccine","volume":"9","author":"Kumar","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0465","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.virol.2012.05.006","article-title":"Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection","volume":"430","author":"Quan","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2018.11.005_bib0470","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/mt.2012.246","article-title":"Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus","volume":"21","author":"Kim","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2018.11.005_bib0475","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1016\/j.vaccine.2014.08.030","article-title":"Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity","volume":"32","author":"Kim","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_bib0480","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.antiviral.2013.01.010","article-title":"Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge","volume":"98","author":"Gao","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.11.005_bib0485","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.4049\/jimmunol.1300954","article-title":"Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination","volume":"191","author":"Hemann","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0490","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.vaccine.2011.12.083","article-title":"Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs","volume":"30","author":"Pyo","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_bib0495","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1080\/21645515.2016.1210729","article-title":"Viral vector-based influenza vaccines","volume":"12","author":"de Vries","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coviro.2018.11.005_bib0500","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2018.11.005_bib0505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007790","article-title":"MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A\/H5N1 viruses at low doses and after single immunization","volume":"4","author":"Kreijtz","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2018.11.005_bib0510","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1086\/595984","article-title":"Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques","volume":"199","author":"Kreijtz","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.11.005_bib0515","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/517614","article-title":"Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1","volume":"195","author":"Kreijtz","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.11.005_bib0520","doi-asserted-by":"crossref","first-page":"7451","DOI":"10.1016\/j.vaccine.2009.05.014","article-title":"Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1)","volume":"27","author":"Yang","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_bib0525","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(06)68076-8","article-title":"Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice","volume":"367","author":"Hoelscher","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2018.11.005_bib0530","doi-asserted-by":"crossref","first-page":"e88340","DOI":"10.1371\/journal.pone.0088340","article-title":"MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses","volume":"9","author":"Hessel","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0535","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/s41598-017-02019-1","article-title":"Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2018.11.005_bib0540","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1128\/JVI.02330-12","article-title":"Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB\/c mice","volume":"87","author":"Mooney","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0545","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1128\/JVI.02321-12","article-title":"Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge","volume":"87","author":"Li","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2018.11.005_bib0555","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3201\/eid2106.150021","article-title":"Induction of influenza (H5N8) antibodies by modified vaccinia virus Ankara H5N1 vaccine","volume":"21","author":"de Vries","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2018.11.005_bib0560","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048322","article-title":"A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years","volume":"7","author":"Antrobus","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2018.11.005_bib0565","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1128\/JVI.01633-16","article-title":"Increased protein degradation improves influenza virus nucleoprotein-specific CD8+ T cell activation in vitro but not in C57BL\/6 mice","volume":"90","author":"Altenburg","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0570","doi-asserted-by":"crossref","first-page":"13418","DOI":"10.1128\/JVI.01219-14","article-title":"Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques","volume":"88","author":"Florek","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0575","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/erv.09.4","article-title":"Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara","volume":"8","author":"Rimmelzwaan","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2018.11.005_bib0580","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/erv.11.188","article-title":"Technologies for enhanced efficacy of DNA vaccines","volume":"11","author":"Saade","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2018.11.005_bib0585","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.coviro.2018.11.005_bib0590","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.vaccine.2010.01.029","article-title":"Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin","volume":"28","author":"Smith","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0595","article-title":"New kids on the block: RNA-based influenza virus vaccines","volume":"6","author":"Scorza","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.coviro.2018.11.005_bib0600","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.4161\/hv.25181","article-title":"A novel, disruptive vaccination technology: self-adjuvanted RNActive((R)) vaccines","volume":"9","author":"Kallen","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coviro.2018.11.005_bib0605","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0610","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2018.11.005_bib0615","doi-asserted-by":"crossref","first-page":"10394","DOI":"10.1128\/JVI.77.19.10394-10403.2003","article-title":"An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector","volume":"77","author":"Perri","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_bib0620","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/bs.adgen.2014.10.005","article-title":"Self-amplifying mRNA vaccines","volume":"89","author":"Brito","year":"2015","journal-title":"Adv Genet"},{"key":"10.1016\/j.coviro.2018.11.005_bib0625","doi-asserted-by":"crossref","DOI":"10.1038\/emi.2013.54","article-title":"Rapidly produced SAM((R)) vaccine against H7N9 influenza is immunogenic in mice","volume":"2","author":"Hekele","year":"2013","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.coviro.2018.11.005_bib0630","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2018.11.005_bib0635","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/JVI.01786-15","article-title":"Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin","volume":"90","author":"Brazzoli","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.11.005_sbref0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161193","article-title":"Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge","volume":"11","author":"Magini","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2018.11.005_bib0645","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2018.11.005_bib0650","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006368","article-title":"Synthetic generation of influenza vaccine viruses for rapid response to pandemics","volume":"5","author":"Dormitzer","year":"2013","journal-title":"Sci Transl Med"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625718301135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625718301135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:01:03Z","timestamp":1761818463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625718301135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":130,"alternative-id":["S1879625718301135"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2018.11.005","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Broadly protective influenza vaccines: design and production platforms","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}